Αποτελέσματα Αναζήτησης
Η μολνουπιραβίρη (molnupiravir) ενδείκνυται για τη θεραπεία της ήπιας έως μέτριας βαρύτητας της νόσου του κορωνοϊού 2019 (COVID-19) σε ενήλικες με θετικό διαγνωστικό τεστ SARS-COV-2 και που έχουν ...
13 Σεπ 2024 · Learn about Lagevrio (molnupiravir) and Paxlovid (nirmatrelvir / ritonavir), two oral antiviral treatments for mild to moderate COVID-19. Compare their effectiveness, side effects, interactions, and cost.
19 Νοε 2021 · EMA issued this advice to support national authorities who may decide on possible early use of the medicine prior to marketing authorisation, for example in emergency use settings, in light of rising rates of infection and deaths due to COVID-19 across the EU.
13 Απρ 2022 · What does molnupiravir cost? In the US a five day course costs around $700 (£540), which the Institute for Clinical and Economic Review estimates equates to $63 000 for each hospital admission averted in that country. 17 “The value—both clinical and economic—of these treatments depends on how much risk patients are at for progressing to ...
Molnupiravir is a new oral antiviral for treating COVID-19 in outpatient settings. This study evaluated the cost-effectiveness profile of molnupiravir versus best supportive care in the treatment of adult patients with mild-to-moderate COVID-19 at risk of progression to severe disease, from a US payer's perspective.
16 Δεκ 2021 · Molnupiravir, the orally bioavailable prodrug of N4-hydroxycytidine (NHC), begins to address this need.
9 Σεπ 2024 · We aimed to report the effect of molnupiravir treatment for COVID-19 on wellbeing, severe and persistent symptoms, new infections, health care and social service use, medication use, and time off work at 3 months and 6 months post-randomisation.
